Pathstone Holdings
NVCR icon

Pathstone Holdings’s NovoCure NVCR Stock Holding History

Pathstone Holdings’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,607
Closed -$227K – 2347
2024
Q4 		$227K Buy
+7,607
New +$161K ﹤0.01% 2109
2024
Q2 		– Sell
-10,559
Closed -$165K – 2358
2024
Q1 		$165K Buy
+10,559
New +$155K ﹤0.01% 2177

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Pathstone Holdings's NVCR Position: Q1 2025 in Review

Pathstone Holdings sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 7,607 shares — an estimated $227K sold.

Pathstone Holdings first reported a position in NVCR in Q1 2024 and held it in 2 quarters. The position peaked at $227K in Q4 2024. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • Pathstone Holdings reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • Pathstone Holdings sold 7,607 NovoCure shares in Q1 2025, an estimated $227K.
  • Pathstone Holdings first reported a position in NovoCure in Q1 2024 and held it in 2 quarters.
  • Pathstone Holdings's NovoCure position peaked at $227K in Q4 2024.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Pathstone Holdings's 13F filing for Q1 2025, filed 15 May 2025.